Additional file 7: of Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer

Table S2. Analysis of screen and TCGA data. (a) NGS analysis with MaGeck (significant candidate sgRNAs with FDR cutoff 0.1 and high_in_treatmentâ =â true). (b) list of converted screen sgRNA candidates to official gene symbols, (c) Candidate genes with clinical amplification on CNA based on Comprehensive analysis of muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms on CbioPortal. (XLSX 9460 kb)补充表S2 筛选数据集与癌症基因组图谱（TCGA, The Cancer Genome Atlas）数据分析。(a) 基于MaGeck工具的下一代测序（NGS, Next-Generation Sequencing）分析：筛选错误发现率（FDR, False Discovery Rate）阈值为0.1且治疗组高表达的显著候选向导RNA（sgRNA, single-guide RNA）；(b) 将筛选得到的候选sgRNA转换为官方基因符号的对应列表；(c) 基于cBioPortal（cBio Cancer Genomics Portal）平台上「多癌症基因组图谱分析平台整合解析肌肉浸润性膀胱癌」研究数据，筛选出存在临床相关性拷贝数扩增（CNA, Copy Number Aberration）的候选基因。（XLSX格式，文件大小9460 KB）